Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer …

JW Neal, SE Dahlberg, HA Wakelee, SC Aisner… - The Lancet …, 2016 - thelancet.com
Background Erlotinib is approved for the treatment of all patients with advanced non-small-
cell lung cancer (NSCLC), but is most active in the treatment of EGFR mutant NSCLC …
被引用次数：137 相关文章

Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer …

JW Neal, SE Dahlberg, HA Wakelee… - The Lancet …, 2016 - ohiostate.elsevierpure.com
Background Erlotinib is approved for the treatment of all patients with advanced non-small-
cell lung cancer (NSCLC), but is most active in the treatment of EGFR mutant NSCLC …

Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer …

JW Neal, SE Dahlberg, HA Wakelee… - The Lancet …, 2016 - pubmed.ncbi.nlm.nih.gov
Background Erlotinib is approved for the treatment of all patients with advanced non-small-
cell lung cancer (NSCLC), but is most active in the treatment of EGFR mutant NSCLC …

[引用][C] Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer …

JW Neal, SE Dahlberg, HA Wakelee, SC Aisner… - The Lancet …, 2016 - cir.nii.ac.jp
Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of
patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a …

Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer …

JW Neal, HA Wakelee, SE Dahlberg, M Bowden… - The Lancet …, 2016 - elibrary.ru
Background Erlotinib is approved for the treatment of all patients with advanced non-small-
cell lung cancer (NSCLC), but is most active in the treatment of EGFR mutant NSCLC …

Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer …

JW Neal, SE Dahlberg, HA Wakelee, SC Aisner… - The Lancet …, 2016 - infona.pl
Erlotinib is approved for the treatment of all patients with advanced non-small-cell lung
cancer (NSCLC), but is most active in the treatment of EGFR mutant NSCLC. Cabozantinib …
[HTML] nih.gov

[HTML][HTML] Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-or third-line treatment of patients with EGFR wild-type advanced non-small cell lung cancer …

JW Neal, SE Dahlberg, HA Wakelee… - The Lancet …, 2016 - ncbi.nlm.nih.gov
Background Erlotinib is approved for the treatment of all patients with advanced non-small
cell lung cancer (NSCLC), but is most active in the treatment of EGFR mutant NSCLC …

Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer …

JW Neal, SE Dahlberg… - The lancet …, 2016 - scholarship.libraries.rutgers.edu
Abstract Lung Neoplasms-drug therapy Anilides-therapeutic use Pyridines-administration &
dosage Lung Neoplasms-mortality Humans Middle Aged ErbB Receptors-genetics Erlotinib …

Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer …

JW Neal, SE Dahlberg, HA Wakelee… - The Lancet …, 2016 - researchwithrutgers.com
Background Erlotinib is approved for the treatment of all patients with advanced non-small-
cell lung cancer (NSCLC), but is most active in the treatment of EGFR mutant NSCLC …

Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer …

JW Neal, SE Dahlberg, HA Wakelee, SC Aisner… - The Lancet …, 2016 - Elsevier
Background Erlotinib is approved for the treatment of all patients with advanced non-small-
cell lung cancer (NSCLC), but is most active in the treatment of EGFR mutant NSCLC …